While evading antitumor immunity is a hallmark of the progression of cancer [6], immunotherapy studies have focused on the role of the PD-1/PD-L1 pathway in maintaining immunosuppression in the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.